Loading page content…
Loading page content…
| Source: | Find a Tender Service (FTS) |
| Notice Type: | Award notice |
| Buyer: | The Royal Marsden NHS Foundation Trust |
| Main Category: | Goods |
| Procurement Method: | Direct award |
| Tender Status: | Complete |
| Estimated Value (ex. VAT): | Not specified |
| Release Date: | 24 October 2025 |
| Application Deadline: | — |
| Procurement ID (OCID): | ocds-h6vhtk-05d335 |
| Notice Reference: | 068116-2025 |
View Original Notice
Access the full notice on the official portal
CAR-T treatment called Obecel developed to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL) which has recently become available to patients. The decision which treatment is most suitable applicable to a specific age group is a clinical one that would be decided by a Multi-Disciplinary Team (MDT). The product should meet strict NHS England standards for cryogenic storage and handling and RMH has such credentials.
Published contracts in the last 12 months
34
total contracts
£7.9m
total value
£1,126,000
average contract size
Typical categories
Prior Information Notice (PIN) for an innovation partnership to develop Artificial Intelligence (AI) in mammography
The Royal Marsden NHS Foundation Trust · WAC-148670
The Royal Marsden NHS Foundation Trust Magazine Design and Print
The Royal Marsden NHS Foundation Trust · WAC-148847
Pipeline status
Not addedContract imported automatically · AI writes the response
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →